University of Texas's MD Anderson Cancer Center: Therapies Targeting DNA Damage Response Show Promising Antitumor Activity
April 11, 2022
April 11, 2022
NEW ORLEANS, Louisiana, April 11 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on April 10, 2022:
* * *
New data from MD Anderson-led studies on ATR inhibitor and next-generation PARP1 inhibitor presented at AACR Annual Meeting
* * *
Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers -- ATR inhibitor elimusertib and PARP in . . .
* * *
New data from MD Anderson-led studies on ATR inhibitor and next-generation PARP1 inhibitor presented at AACR Annual Meeting
* * *
Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers -- ATR inhibitor elimusertib and PARP in . . .